Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
Authors:
- Juan Guerrero-MauvecinJGJuan Guerrero-Mauvecin
- Natalia Villar-GómezNVNatalia Villar-Gómez
- Lucia Miño-IzquierdoLMLucia Miño-Izquierdo
- Adrián Povo-RetanaAPAdrián Povo-Retana
- Adrian M. RamosARAdrian M. Ramos
- Gema Ruiz-HurtadoGRGema Ruiz-Hurtado
- Maria D. Sanchez-NiñoMaria D. Sanchez-Niño
- Alberto OrtizAOAlberto Ortiz
- Ana B. SanzASAna B. Sanz
Open Access
- 9 June 2025
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 701
Abstract
The cardiovascular–kidney–metabolic (CKM) syndrome was recently conceptualized to provide a holistic framework for diagnosing and treating the full spectrum of key age-associated interrelated conditions: overweight/obesity, type 2 diabetes mellitus, acute and chronic kidney disease, and cardiovascular disease. This conceptualization resulted from epidemiological associations, advances in our understanding of shared and interrelated pathogenic mechanisms, and observations that several drug families improved outcomes in all three components of CKM. Sodium/glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) enhance all CKM spectrum components, although their efficacy varies against specific components. However, the modified mechanisms by these drugs beyond glycemic control in CKM syndrome are poorly understood. We now deeply review the available literature regarding the impact of SGLT2i on oxidative stress and antioxidant defenses in preclinical and clinical studies of type 2 diabetes mellitus, acute and chronic kidney disease, cardiovascular disease, and CKM syndrome. Evidence suggests that SGLT2i may have a secondary antioxidant effect that reduces the vicious cycle of tissue injury—inflammation—tissue injury, even in organs distant from the primary injury.Keywords
Funding Information
- Instituto de Salud Carlos III (ISCIII) (PI22/00050, PI21/00251, PI19/00588, PI19/00815, PI21/01453, PI23/00182, PMP21/00109, AC22/00027, RD21/0005/0001, RD24/0004/0018, 101101220, CNS2023-144891)
- European Union (PI22/00050, PI21/00251, PI19/00588, PI19/00815, PI21/01453, PI23/00182, PMP21/00109, AC22/00027, RD21/0005/0001, RD24/0004/0018, 101101220, CNS2023-144891)
- COST (European Cooperation in Science and Technology) (PI22/00050, PI21/00251, PI19/00588, PI19/00815, PI21/01453, PI23/00182, PMP21/00109, AC22/00027, RD21/0005/0001, RD24/0004/0018, 101101220, CNS2023-144891)
- European Health and Digital Executive Agency (PI22/00050, PI21/00251, PI19/00588, PI19/00815, PI21/01453, PI23/00182, PMP21/00109, AC22/00027, RD21/0005/0001, RD24/0004/0018, 101101220, CNS2023-144891)
- Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (MICIU) (PI22/00050, PI21/00251, PI19/00588, PI19/00815, PI21/01453, PI23/00182, PMP21/00109, AC22/00027, RD21/0005/0001, RD24/0004/0018, 101101220, CNS2023-144891)
This publication has 136 references indexed in Scilit:
- Dapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting FerroptosisESC Heart Failure, 2024
- Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar ratsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patternsDiabetologia, 2024
- Estimated Glomerular Filtration Rate, Albuminuria, and Adverse OutcomesJAMA, 2023
- Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure: Potential Decongestive Mechanisms and Current Clinical StudiesEuropean Journal of Heart Failure, 2023
- Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expressionNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Oxidative Stress in the Cardiorenal Metabolic SyndromeCurrent Hypertension Reports, 2012
- Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the HeartArchives of internal medicine (1960), 2004
- Urinary excretion of 8-oxo-7, 8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathyDiabetologia, 2002
- Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune statusThe Lancet, 1993